As organizations in life sciences continue to grow and evolve, the strategies they use to reach healthcare providers (HCPs) and patients are following suit. Doctors and patients are inundated with more and more information across digital and traditional channels about relevant diseases, gold-standard treatments, and their various benefits.

To create a market assessment, more and more brand strategists are moving towards the use of RWD and RWE. In this blog, we walk through a hypothetical example – sizing the market for Hemophilia A – doing just that.  Creating a market assessment is a critical step in commercializing a new drug. This is because…

Developing, testing and getting approval for a new drug is a tough feat – but only half the battle. Now that your new drug is ready to be commercialized, you have to get it to the right patients, which starts with finding the right physicians. Here’s how this process works – and how to use…

On December 1st each year the world unites to commemorate World AIDS Day to support those living with HIV and honor the memory of those who died from AIDS-related illnesses. This year’s theme is “Equalize” to inform people globally of inequalities as one of the growing challenges. Enormous progress has been made in the treatment,…

Today, the number of Americans aged 65 and older living with Alzheimer’s dementia is estimated at 6.2 million. Without medical breakthroughs to slow or cure the disease, it is projected to approach 13.8 million by 2060. Alzheimer’s is the fifth-leading cause of death among Americans aged 65 and older and in the past twenty years,…

Today, more than 130 million adults in the United States are dealing with the health consequences of living with prediabetes and diabetes.

When the pandemic struck in 2019, there were more than 51 million Americans experiencing some type of mental illness.

We looked at three of the leading medications belonging to the Interleukin antagonists group used to treat this condition that specifically treat psoriasis: secukinumab, risankizumab, and ixekizumab.

Why is it so complicated? Why can’t kidney transplant patients find the right donors? Or get the life-saving medical procedures they need when they need it? Let’s find out.